View
35
Download
0
Category
Preview:
Citation preview
FX CorDiax At the heart of long-term haemodialysis
Protecting the Endothelium
Protect your patient
Innovative Helixone®plus membraneOptimised membrane porosity for enhanced middle molecule removal
Unique FX-class® designFacilitates the best in cardioprotective haemodialysis therapy
Outstanding endotoxin retentionPrevents the transfer of endotoxins into patients blood
Unique INLINE steam sterilisationNo chemical residuals
Designed to Dialyse.
Built for Cardioprotection.
The new FX CorDiax
Innovative Helixone®plus membraneAdvances in fibre design allow better removal
of uremic toxin
Inner surface
Support region
Close-up of the inner surface and the support region of the membrane.
The new membrane structure of Helixone®plus allows the
easy passage of middle molecules across the more porous
support region of the membrane.
The fibre support region underneath the inner surface has
been opened up, optimising porosity and therefore the
convective filtration, flushing of larger uremic toxins such as
β2-microglobulin ( ≈ 11,800 Da) or myoglobin
( ≈ 17,000 Da).
At the same time the retention of beneficial molecules such
as albumin is improved.
The reduced transmembrane resistance improves the
removal of a broad range of middle molecules as well as
low molecular weight substances.
Comparison of sieving coefficient data of FX 60 and FX CorDiax 60
FX CorDiax 60 FX 60 S
ievi
ng C
oeffi
cien
t
Molecular Mass/Dalton
SCMyo 0.50
SCMyo 0.28
SCβ2-m 0.80
SCβ2-m 0.90
1,000 10,000 100,000
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
Comparison of sieving coefficients of FX CorDiax, Xevonta Hi, PolyfluxTM H, and ElisioTM-H.
(All data taken from manufacturer’s brochures. 1) > 0.8, 2) < 0.001, 3) < 0.01)
Sie
ving
Coe
ffici
ent
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
β2-microglobulin
(11,731 Da)
n.a.
FX CorDiax
FX CorDiax
Xevonta Hi
Xevonta Hi
PolyfluxT
M H
PolyfluxT
M H
ElisioTM -H
ElisioTM -H
Myoglobin
(17,053 Da)
n.a. n.a.
1)
Sie
ving
Coe
ffici
ent o
f Alb
umin
FX CorDiax
Xevonta Hi
PolyfluxT
M H
ElisioTM -H
Albumin
(66,500 Da)
0.014
0.012
0.010
0.008
0.006
0.004
0.002
02) 2)
3)
Homogenous bloodflow path
AdvancedHelixone®plus membrane
3-dimensional wave structureof the fibre
Radial dialysate flow
Reference1. Weber V. et al., Blood Purif (2003); 21: 365.2. Shintani H. et al., Journal of Analytical Toxicology (1989); 13: 354-357.3. Müller T. F. et al., Nephron (1998); 78: 139-142.
Unique FX-class® design
Outstanding endotoxin retention
Optimised dialysate flowThe 3-dimensional microwave structure, in combination with
the design of dialyser housing, ensures uniform dialysate
flow. This improves clearance values and the overall filter
performance.
Better haemodynamicsThe refined blood inlet port improves haemodynamics and
the new design eliminates the risk of bloodline kinking.
Environmentally friendlyThe FX-class® dialysers weigh less than 50% of previous
dialysers and use ecologically friendly materials.
Greater protection through active preventionMembranes such as Helixone®, which have a high
endotoxin retention capacity1, protect the patient from
inflammation, particularly when ultrapure dialysate is not
available.
Amyloidosis, immune disorders, or accelerated
atherosclerosis can be the result of using a membrane
with a low endotoxin retention capacity, and inflammation
can lead to an increased need for EPO.
Unique INLINE steam sterilisation
Clean and safeFX-class® dialysers are sterilised using the unique INLINE
steam sterilisation process specifically developed by
Fresenius Medical Care.
This protects your patient from cytotoxic and carcinogenic
residuals2 caused by degraded and altered material inside
the dialyser produced during gamma sterilisation.
A further effect of this clean and safe process is the reduced
activation of the complement system3 and the low rinsing
volume helps reduce costs and preparation time.
Reference1. Tattersall J. et al., Nephrol Dial (2007); 22(Suppl.2); ii5-ii21.2. Locatelli F. et al., Journal of American Society of Nephrology (2009); 20: 645-654.3. Pedrini L. A. et al., Nephrol Dial Transplant (2011); 26(8): 2617-2624.
Improved Survival – Better Outcomes
The use of High-Flux membranes such as FX-class® High-Flux
dialysers improves patient survival rates.
Enhanced middle molecule removal contributes to a reduction
of the complications of haemodialysis as well as improving
long-term patient outcomes.1
The results of the MPO study indicate the beneficial effect of High-Flux membranes in terms of reduced mortality for patients with serum albumin levels ≤ 4.0 g/dL or diabetes.2
Improved patient survival2
Reduced inflammation3
Better anemia control with reduced EPO doses4
Immune dysfunctions may be reversed5
Kaplan-Meier survival curves for the population of patients with serum albumin levels <_ 4.0 g/dL (log-rank test p = 0.032).2 (Graph adapted from original publication)
Sur
viva
l Pro
babi
lity
of P
atie
nts
Months
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
High-Flux Membrane Low-Flux Membrane
Patients with Serum Albumin ≤ 4 g/dL (p = 0.032)
0 12 24 36 60 8448 72
β2-microglobulinAlbumin
4. Bonforte G.et al., Blood Purif (2002); 20: 357-363.5. Lonnemann G. et al., Blood Purif (2003); 21(3): 225-231.
The new FX CorDiax
Performance Data
Sieving coefficients of FX CorDiax
High-Flux Dialysers and HaemodiafiltersMolecular weight
(Dalton)Albumin 66,500
17,053< 0.001
Myoglobin 0.5-microglobulin 11,731
5,200
0.9Inulin 1Membrane material Helixone®plusSterilisation method INLINE steamHousing material PolypropylenePotting compound PolyurethaneUnits per box 24
Clearance (QB = mL/min)
Cytochrome c 12,230Inulin 5,200Vitamin B12 1,355Phosphate 132Creatinine 113Urea 60
Clearance (QB = mL/min)
Cytochrome c 12,230
Vitamin B12 1,355
Creatinine 113
Ultrafiltration coeff. (mL/h x mmHg)Effective surface (m²)K A UreaPriming volume (mL)Article number
FX CorDiax Haemodiafilters
Clearance (QB = 300 mL/min, Q
F = 75 mL/min)
Cytochrome c 12,230Inulin 5,200Vitamin B12 1,355Phosphate 132Creatinine 113Urea 60
60
Clearance (QB = 400 mL/min, QF = 100 mL/min)
Cytochrome c 12,230InulinVitamin B12 1,355
5,200
PhosphateCreatinine 113
132
Urea
Ultrafiltration coeff. (mL/h x mmHg)Effective surface (m²)K A UreaPriming volume (mL)Article number
In vitro performance: QD = 500 mL/min, T = 37°C (EN 1283, ISO 8637). Ultrafiltration coefficients: human blood, Hct 32 %, protein content 6 %.
%, protein content 6 %. In vitro performance: QD = 500 mL/min, Q
F = 0 mL/min, T = 37°C (EN 1283, ISO 8637). Ultrafiltration coefficients: human blood, Hct 32
Inulin 5,200
Phosphate 132
Urea 60
FX CorDiax 60
96116175237252271
100
191
290
471.4
1,16474
F00005651
122
270
319
FX CorDiax 50
7181126173180191
76
144
229
331.088653
F00005650
88
215
255
FX CorDiax 80
111127190248261280
117
209
303
641.8
1,42995
F00005652
CorDiax 800
141156217267277291
160178251321339365
622.0
1,365115
F00005656
135
285
336
FX CorDiax 100
125144207258272283
133
229
321
742.2
1,545116
FX 1000CorDiax
151166225271280292
172190262328343367
762.3
1,421136
F00005657
154
299
341
F00005653
FX CorDiax 120
136149213262274284
145
237
325
872.5
1,584132
160
305
343
F00005654
300200
300 400 400 400
FX FX CorDiax High-Flux Dialysers CorDiax 40
485696142155175
210.654732
F00005649
FX CorDiax 600
131144204257271285
149166235307327354
461.6
1,14895
F00005655
200 300 300
400
300
O
FX
β2
O
Fresenius Medical Care Australia Pty Ltd. · Level 17, 61 Lavender Street, Milsons Point, NSW 2061, Sydney, Australia �Telephone: (61 2) 9466 8000 · Fax: (61 2) 9929 5595 · www.fmc-ag.com A
P3
67
/HD
/AU
/20
14
© c
op
yrig
ht 2
01
3 F
rese
nius
Med
ical
Car
e A
sia
Pac
ific
Lim
ited
Recommended